Banque Pictet & Cie SA Has $3.58 Million Stake in Novo Nordisk A/S $NVO

Key Points

• Banque Pictet & Cie SA increased its stake in Novo Nordisk A/S by 41.4%, owning 51,795 shares valued at approximately $3.58 million after adding 15,170 shares in the second quarter.
• Novo Nordisk A/S reported earnings of $0.97 per share for the last quarter, exceeding expectations, with revenues of $11.69 billion.
• The company announced a dividend of $0.4119 per share, with a dividend payout ratio of 22.53% and a high yield of 240% as of the last payout date.

Banque Pictet & Cie SA lifted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 41.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 51,795 shares of the company's stock after purchasing an additional 15,170 shares during the period. Banque Pictet & Cie SA's holdings in Novo Nordisk A/S were worth $3,575,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Park Square Financial Group LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter worth approximately $29,000. North Capital Inc. bought a new position in shares of Novo Nordisk A/S during the first quarter worth approximately $27,000. Copeland Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares during the period. Stone House Investment Management LLC bought a new position in shares of Novo Nordisk A/S during the first quarter worth approximately $30,000. Finally, Mascagni Wealth Management Inc. bought a new position in shares of Novo Nordisk A/S during the fourth quarter worth approximately $40,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Down 0.8%

NYSE NVO opened at $55.61 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $121.34. The company has a market cap of $248.30 billion, a price-to-earnings ratio of 15.28, a price-to-earnings-growth ratio of 2.12 and a beta of 0.66. The business's fifty day moving average is $56.03 and its 200 day moving average is $64.53.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a $0.4119 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is 22.53%.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Berenberg Bank upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Wednesday, September 17th. HSBC lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective on the stock. in a research note on Thursday, July 31st. BNP Paribas upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research note on Wednesday, August 13th. Barclays restated an "equal weight" rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Finally, Hsbc Global Res lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $81.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.